7 recruiting, 2 completed, 2 withdrawn, 1 available. 5 Phase 2, 4 Phase 3, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Withdrawn 1 |
| Phase 3 | 4 | Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
Follow Urothelial Carcinoma Recurrent: new trials by email Literature Review of Urothelial Carcinoma Recurrent trials Research Report on Urothelial Carcinoma Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC UGN-501 - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 1 | Recruiting | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | 30 | 2026-09-28 | 2026-10-13 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-06-30 | 2026-03-17 | |
| Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Adebrelimab, Trastuzumab Rezetecan - Urothelial Carcinoma, Advanced Urothelial Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 96 | 2025-11-20 | 2026-04-30 |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma 9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 60 | 2025-01-17 | 2025-03-21 |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE - Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Recruiting | Verity Pharmaceuticals Inc. | 540 | 2024-04-24 | 2026-03-20 |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto Jelmyto (mitomycin) for pyelocalyceal solution - Urothelial Carcinoma, Urothelial Carcinoma Recurrent | Recruiting | UroGen Pharma Ltd. | 450 | 2023-11-17 | 2026-09-29 | |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| En Bloc TURBT With Collins Loop vs Conventional TURBT En bloc TURBT Collins Loop, Conventional TURBT - Bladder Cancer, Bladder Neoplasm | Not applicable | Unknown | Hospital Universitario de Fuenlabrada | 80 | 2021-04-01 | 2021-08-30 |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Pemigatinib - Bladder Cancer, NMIBC | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2020-10-02 | 2025-10-03 |
| Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition Vactosertib(TEW-7197)/ Durvalumab - Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma | Phase 2 | Withdrawn | MedPacto, Inc. | 2019-12-13 | 2024-12-09 | |
| Named Patient Program for Mitomycin for Pyelocalyceal Solution Mitomycin for pyelocalyceal solution - Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter | Available | UroGen Pharma Ltd. | 2026-09-15 |
Urinary Bladder Neoplasms (7) · Carcinoma, Transitional Cell (6) · Neoplasms (5) · Non-Muscle Invasive Bladder Neoplasms (4) · Urologic Neoplasms (3) · Recurrence (2) · Carcinoma (1) · Neoplasm Metastasis (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Urogenital Neoplasms (9) · Carcinoma (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Urinary Bladder Diseases (8) · Urologic Neoplasms (7) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Cisplatin (2) · Gemcitabine (2) · Mitomycin (2) · BCG Vaccine (1) · Carboplatin (1) · Imiquimod (1) · Platinum Compounds (1) · durvalumab (1) · pemigatinib (1) · tamibarotene (1) · toripalimab (1)
UroGen Pharma Ltd. (3) · Relmada Therapeutics, Inc. (2) · Hospital Universitario de Fuenlabrada (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · MedPacto, Inc. (1) · Nagoya University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sun Yat-sen University (1) · SystImmune Inc. (1) · UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. (1) · Verity Pharmaceuticals Inc. (1)
United States (6) · China (2) · Spain (2) · Canada (1) · Italy (1) · Japan (1)
Sebastian Mirkin, MD (2) · Adam Feldman, MD (1) · Alexandre R Zlotta, MD, PhD, FRCSC (1) · Girish S Kulkarni, MD (1) · Jimmy Liu Zhao, MD, PhD (1) · Lawrence Fong, MD (1) · Noah M Hahn, MD (1) · Raj S Pruthi, MD MHA FACS (1) · Solomon Woldu, MD (1) · Syusuke Akamatsu (1) · Yair Lotan, MD (1) · Yanxia Shi, Doctor (1)